Abstract
The present study aims to prepare and evaluate the self-nanoemulsifying drug delivery (SNEDDS) system to enhance dissolution rate of a poorly soluble drug dutasteride. The formulation was prepared using capryol PGMC, Cremophor EL, and polyethylene glycol (PEG) 400 as oil, surfactant and co-surfactant, respectively. The pseudo-ternary phase diagrams with presence and absence of drug were plotted to find out the nanoemulsification range and also to evaluate the effect of dutasteride on the emulsification behavior of the phases. Prepared SNEDDS formulations were evaluated for its particle size distribution, nanoemulsifying properties, robustness to dilution, self-emulsification time, turbidity measurement, drug content and in-vitro dissolution. The optimized formulations are further evaluated for heating cooling cycle, centrifugation studies, freeze thaw cycling, particle size distribution and zeta potential were carried out to confirm the stability of the formed SNEDDS formulations. The particle size, zeta potential and polydispersity index of the optimized formulation found to be 35.45 nm, -15.45 and 0.19, respectively. The in vitro results are revealed that the prepared formulation enhanced the dissolution rate of dutasteride significantly as compared with pure drug. Based the results, it was concluded that the dutasteride-loaded SNEDDS shows potential to enhance the dissolution of dutasteride, thus improving the bioavailability and therapeutic effects.
Highlights
Benign prostate hyperplasia (BPH) is the most common benign neoplasm which approximately 80 % of the elderly men develops the microscopic evidence of BPH (Dolder, 2006)
The present study aims to prepare and evaluate the self-nanoemulsifying drug delivery system (SNEDDS) to enhance the dissolution rate of a poorly soluble drug dutasteride
The optimized formulations were evaluated for heating cooling cycle, centrifugation studies, freeze thaw cycling, particle size distribution and zeta potential to confirm the stability of the formed SNEDDS formulations
Summary
Benign prostate hyperplasia (BPH) is the most common benign neoplasm which approximately 80 % of the elderly men (above 60 years old) develops the microscopic evidence of BPH (Dolder, 2006). Half of the patients develop enlarged prostate gland, followed by symptoms such as nocturia, increase in urinary urgency and frequency, and reduced force of stream. For patients with enlarged prostate, the treatment would be invasive surgery and prostatectomy. The treatment would be to stop the static factor of prostate gland enlargement, which is dihydrotestosterone (DHT). DHT is a potent androgen, which is converted from testosterone to androstenedione. Inhibition of DHT formation can be a treatment strategy to reduce prostate size.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
